Autolus Therapeutics plc is a London-based biopharmaceutical company focused on pioneering T cell therapies for cancer treatment. It's known for its innovative approach in developing therapies that target specific types of cancer cells, with its leading program, obecabtagene autoleucel, showing promise in adult and pediatric acute lymphoblastic leukemia (ALL). Additionally, Autolus is exploring treatments for peripheral T-cell lymphoma and neuroblastoma, among others, through its diverse pipeline of investigational therapies. Founded in 2014, the company is at the forefront of utilizing T cell engineering to combat cancer.